---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Calcineurin inhibitors"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Calcineurin inhibitors. Topics: International guideline: ciclosporin for CSU unresponsive to licensed treatments, off-label; International guideline: ciclosporin adverse effects, embryotoxicity, and comparison with long-term corticosteroids; Draft joint task force guideline: calcineurin inhibitor after advanced systemic therapy; Cyclosporine meta-analysis: response rates and dose-dependent adverse events; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/calcineurin-inhibitors"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Calcineurin inhibitors

<a id="heading-2.2.2.1.5"></a>

## 2.2.2.1.5 Calcineurin Inhibitors

<a id="topic-2.2.2.1.5-1"></a>

### International guideline: ciclosporin for CSU unresponsive to licensed treatments, off-label

> “Patients with CSU who do not show sufficient benefit from treatment with H1‐antihistamines, especially if they are also unresponsive to omalizumab, can alternatively be treated with ciclosporin 3–5 mg/kg per day.”
> “Ciclosporin is off‐label for urticaria and is recommended only for patients with severe disease refractory to any other licensed treatments.”
> “We suggest using ciclosporin”
> “for the treatment of patients with CU unresponsive to licensed treatments or if these are not available.”
> “currently not licensed for CU”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.5-2"></a>

### International guideline: ciclosporin adverse effects, embryotoxicity, and comparison with long-term corticosteroids

> “but this drug cannot be recommended as standard treatment due to a higher incidence of adverse effects, especially with long‐term use”
> “However, ciclosporin has a far better risk/benefit ratio compared to long‐term use of steroids.”
> “ciclosporin, although not teratogenic, is embryotoxic in animal models and is associated with preterm delivery and low birth weight in human infants.”
> “Ciclosporin can be especially effective in selected patients with CSUaiTIIb with low total IgE levels and other markers of autoimmunity”

Source: [Zuberbier et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466004/)

<a id="topic-2.2.2.1.5-3"></a>

### Draft joint task force guideline: calcineurin inhibitor after advanced systemic therapy

> “advanced systemic therapy, the panel suggests adding a calcineurin inhibitor rather than not adding one.”
> “rather than adding an oral calcineurin inhibitor such as cyclosporine or”
> “Calcineurin inhibitors may also serve as a longer bridge or later-line control strategy when”

Source: [AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026)](https://college.acaai.org/wp-content/uploads/2026/06/JTF-CU_guideline-2026-06-01-For-Distribution.pdf)

<a id="topic-2.2.2.1.5-4"></a>

### Cyclosporine meta-analysis: response rates and dose-dependent adverse events

> “Eighteen studies (909 participants) including 2 randomized controlled trials were included, with 125, 363, and 266 patients with CSU receiving very low (<2 mg/kg/d), low (from 2 to< 4 mg/kg/d), and moderate (4-5 mg/kg/d) doses of CsA, respectively.”
> “The overall response rate to CsA treatment with low to moderate doses at 4, 8, and 12 weeks was 54%, 66%, and 73%, respectively.”
> “Among patients treated with very low, low, and moderate doses of CsA, 6%, 23%, and 57% experienced 1 or more adverse event, respectively.”
> “Given the limited number and quality of studies, our results should be interpreted with caution.”
> “We suggest that the appropriate dosage of CsA for CSU may range from 1 to 5 mg/kg/d, and 3 mg/kg/d is a reasonable starting dose for most patients.”

Source: [Kulthanan et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/28916431/)

<a id="topic-2.2.2.1.5-5"></a>

### Network meta-analysis for the joint task force guideline: cyclosporine effective but among the most harmful

> “As part of updating the AAAAI/ACAAI JTFPP chronic urticaria guidelines”
> “Cyclosporine may be among the most effective for improving urticaria activity but may be among the most harmful in increasing the frequency of any adverse events.”

Source: [Chu et al. (2025a)](https://doi.org/10.1016/j.jaci.2025.06.004)

<a id="topic-2.2.2.1.5-6"></a>

### Predictors of response to cyclosporine: systematic review

> “This study aimed to systemically review literature relating to factors that could potentially predict a favorable response to cyclosporine A (CsA) treatment for chronic spontaneous urticaria (CSU).”
> “A total of 13 studies (404 patients with CSU and 200 healthy patients) were included.”
> “Since most positive results were from non-RCT articles and some data were still inconsistent, this systematic review identified no reliable practical biomarker for predicting CsA treatment response in patients with CSU.”

Source: [Kulthanan et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6658402/)

<a id="topic-2.2.2.1.5-7"></a>

### Type IIb autoimmune CSU: good response to cyclosporine

> “Type IIb autoimmune CSU is characterized by higher disease severity, concomitant autoimmune diseases, low levels of total IgE, elevated levels of IgG-anti–thyroid peroxidase, basopenia, eosinopenia, poor response to antihistamines and to omalizumab, and a good response to cyclosporine.”

Source: [Kolkhir et al. (2022b)](https://doi.org/10.1016/j.jaci.2022.04.010)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
